Try our Advanced Search for more refined results

In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. March 18, 2021

    Opioid Distributors Argue 'Nuisance' Trial Theory Is Nonstarter

    Opioid distributors fighting to end an upcoming bellwether trial before it starts told a West Virginia federal judge Thursday that the "public nuisance" claim anchoring the case doesn't actually apply.

  2. March 08, 2021

    McKinsey Seeks New MDL As Opioid Headaches Worsen

    An emerging wave of lawsuits accusing McKinsey & Co. of contributing to the opioid crisis should be centralized but also kept separate from existing multidistrict opioid litigation, the beleaguered consulting firm said in new court filings.

  3. March 05, 2021

    Opioid Litigation Is Prying Open Vaults Of Big Pharma Secrets

    In an unveiling with few historical parallels, major pharmaceutical corporations are poised to settle sweeping opioid litigation by agreeing to publicize millions of pages of internal documents illustrating how they marketed and sold narcotic painkillers amid a dire addiction epidemic, according to lawyers and court records.

  4. February 24, 2021

    As McKinsey Is Dragged Into MDL, Fresh Atty Tensions Arise

    Newly filed cases accusing McKinsey & Co. of inflaming the opioid crisis contain the clearest signs yet that tribes and local governments will pull the consulting powerhouse into multidistrict opioid litigation, where fresh discord emerged Wednesday among plaintiffs attorneys.

  5. February 16, 2021

    Parents Ask Judge To Rethink Cert. Denial For 'Opioid Babies'

    Legal guardians and parents of babies born to mothers who took opioids while pregnant urged an Ohio federal judge on Tuesday to rethink a ruling refusing their class certification request, saying he made clear errors in judgment.

  6. February 10, 2021

    Teva 'Not Optimistic' About Sealing $23B Opioid Deal Soon

    Teva Pharmaceuticals probably won't finalize a major opioid settlement until the coronavirus pandemic abates and allows for the resumption of courtroom trials that tend to bring litigants to the negotiating table, the drugmaker's chief executive said Wednesday.

  7. February 01, 2021

    'Opioid Babies' Can't Get Class Certification In MDL

    The Ohio federal judge overseeing the multidistrict litigation over the opioid crisis on Monday refused to sign off on a class of legal guardians of babies born to mothers who took opioids during pregnancy, saying the definitions of the class are too inconsistent and imprecise.

  8. January 27, 2021

    Judge Polster Talks Senior Status And Opioid MDL's Future

    On the cusp of assuming senior status, U.S. District Judge Dan Aaron Polster spoke with Law360 on Wednesday about his plans for continued oversight of historic opioid litigation and why the time is right to open up a judicial seat for the new Democratic president to fill.

  9. January 14, 2021

    6th Circ. Won't Stop Ex-FDA Chief's Opioid MDL Testimony

    The Sixth Circuit said on Thursday that it won't stop a lower court from forcing a former U.S. Food and Drug Administration director to be deposed in multidistrict opioid litigation before he clocks in to work in an unspecified role in the Biden administration.

  10. January 11, 2021

    Ex-FDA Chief Getting Biden Admin. Post, Opioid Atty Says

    A former U.S. Food and Drug Administration leader under two presidents is expected to be named soon to a full-time post in the Biden administration, a lawyer said Monday in multidistrict opioid litigation during a battle over the onetime FDA boss' testimony.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!